ProfileGDS5678 / 1453312_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 97% 97% 97% 96% 96% 98% 98% 97% 97% 97% 97% 97% 97% 97% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 19.5727697
GSM967853U87-EV human glioblastoma xenograft - Control 29.4326197
GSM967854U87-EV human glioblastoma xenograft - Control 39.346197
GSM967855U87-EV human glioblastoma xenograft - Control 49.1136896
GSM967856U87-EV human glioblastoma xenograft - Control 58.857596
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 19.6118598
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 29.8693498
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 39.4610997
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 49.3498897
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 19.2852197
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 29.579297
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 39.3504597
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 49.3916397
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 59.1735197